New biosimilar Gotenfia approved for inflammatory conditions in Europe.
- Gotenfia is a new biosimilar approved in Europe
- Targets serious inflammatory conditions
- Developed by STADA and Bio-Thera
STADA and Bio-Thera have announced that Gotenfia, a biosimilar to Simponi, has received marketing authorization from the European Commission. This new drug is designed to treat various serious inflammatory conditions, providing patients with an alternative treatment option. Biosimilars like Gotenfia aim to offer more cost-effective solutions while maintaining similar efficacy and safety profiles as their reference therapies.
The approval of Gotenfia is part of a growing trend in Europe towards the use of biosimilars, which can help increase access to important therapies for patients suffering from chronic conditions. The collaboration between STADA and Bio-Thera highlights the ongoing advancements in biopharmaceuticals and their potential to improve patient care across the continent.
